INDSWFTLAB · NSE
Ind-Swift Laboratories Limited
₹373.25
-1.32% (-₹5)
Prev. close
₹378.25
Volume
3,99,757
Delivery %
45.2%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Ind-Swift Laboratories, advising investors to buy, hold, and accumulate the stock. He expects an upside of 21…” | Rajesh PalviyaAxis Securities | Ind-Swift Laboratories Ltd | HIT |
Fundamentals
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Navrattan R. Munjal
Headquarters
Manimajra
Employees
1,388
Website
indswiftlabs.comExchange
View on NSE ↗Key stats
Market cap
₹3,245.84 Cr
P/E ratio (TTM)
55.7
EPS (TTM)
₹6.70
Beta (1Y · daily vs NIFTY 50)
0.87
Beta (5Y · monthly vs NIFTY 50)
0.88
Shares float
3.36 Cr
EPS · quarter ended Jun 2026
₹2.84
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹856.58 Cr | ₹1,038.73 Cr | ₹1,207.31 Cr | ₹1,709.15 Cr | ₹561.71 Cr | ₹641.29 Cr | |
| EBITDA | ₹203.62 Cr | ₹239.10 Cr | ₹230.28 Cr | ₹776.43 Cr | ₹285.20 Cr | ₹81.06 Cr |
| ₹-4.40 Cr | — | ₹47.60 Cr | ₹538.75 Cr | ₹250.48 Cr | ₹43.12 Cr | |
| Diluted EPS | ₹-0.74 | ₹-0.36 | ₹-4.28 | ₹91.18 | ₹35.21 | ₹5.03 |
Net income has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,818.00 Cr | ₹1,801.00 Cr | ₹1,824.00 Cr | ₹1,165.00 Cr | ₹1,438.00 Cr | ₹1,673.00 Cr | |
| — | ₹952.99 Cr | ₹862.10 Cr | ₹216.80 Cr | ₹32.98 Cr | ₹17.91 Cr | |
| Stockholders' equity | ₹604.00 Cr | ₹601.00 Cr | ₹682.00 Cr | ₹931.00 Cr | ₹1,173.00 Cr | ₹1,384.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹135.00 Cr | ₹150.00 Cr | ₹195.00 Cr | ₹-163.00 Cr | ₹-25.00 Cr | ₹-70.00 Cr | |
| Investing cash flow | ₹-10.17 Cr | ₹4.77 Cr | ₹-13.37 Cr | ₹-27.15 Cr | ₹-113.13 Cr | ₹-72.68 Cr |
| ₹-124.00 Cr | ₹-141.00 Cr | ₹-186.00 Cr | ₹699.00 Cr | ₹69.00 Cr | ₹142.00 Cr | |
| Capital expenditure | ₹-10.68 Cr | ₹-18.41 Cr | ₹-12.77 Cr | ₹-73.01 Cr | ₹-64.41 Cr | ₹-87.72 Cr |
| End cash position | — | — | ₹17.07 Cr | ₹477.19 Cr | ₹425.11 Cr | ₹429.85 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 24(15Q) | Mar 25–Jun 25(3Q) | Jul 25 | Jul 25 | Aug 25 | Aug 25–Dec 25(3Q) | Feb 26 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 42.00% | 40.94% | 38.57% | 36.77% | 37.72% | 39.50% | 43.06% | 42.99% | 42.93% |
| Public | 58.00% | 59.06% | 61.43% | 63.23% | 62.28% | 60.50% | 56.94% | 57.01% | 57.07% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Ind-Swift Laboratories Limited | ₹3,377.94 Cr | ₹385.35 | 58.0 | 2.44 | 3.1% | 0.01 | +11.4% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Gennex Laboratories Share Price Up 10.09%: Full Analysis
Gennex Laboratories Ltd. shares rose 10.09% to Rs 12.88, increasing its market capitalization to Rs 285.95 crore. This move positioned the micro-cap stock among notable gainers in today's trading session. The company's P/E ratio is 14.66 and its P/B ratio is 1.25, with an ROE of 10.71% and ROCE of 13.24%.